- Home
- SABR vs ACHV Comparison
SABR vs ACHV Comparison
Compare SABR & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | ACHV |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 811.2M | 726.5M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SABR | ACHV |
|---|---|---|
| Price | $1.81 | $7.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $2.11 | ★ $14.15 |
| AVG Volume (30 Days) | ★ 5.8M | 1.3M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,866,956,000.00 | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $4.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $2.62 |
| 52 Week High | $2.50 | $8.64 |
Technical Indicators
Market Signals| Indicator | SABR | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 41.70 |
| Support Level | $1.68 | $6.92 |
| Resistance Level | $1.99 | $7.11 |
| Average True Range (ATR) | 0.09 | 0.38 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 16.04 | 13.10 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.